Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amphastar Buys International Medication Systems | Contract Pharma

What are you searching for?

Sign in

Amphastar Buys International Medication Systems

Picks ups 33 injectable products in the UK

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amphastar Pharmaceuticals, through its wholly owned UK subsidiary, Amphastar UK Limited, acquired a UK-based corporation, International Medication Systems (UK) Limited, including its product trademarks, and other related product assets, as well as marketing authorizations for thirty-three products in the UK, Ireland, Australia, and New Zealand, representing eleven different injectable chemical entities, from UCB Pharma GmbH for $7.7 million. The products are generic injectables containing the following active ingredients: adrenaline, amiodarone, atropine, calcium chloride, furosemide, glucose, lidocaine, magnesium sulphate, morphine, naloxone and sodium bicarbonate. Amphastar plans to transfer the products to its facilities in California. The transfer will require UK MHRA and other related regulatory agency approval before the products can be re-launched.

“We are very happy to be able to expand our presence into the international market with this transaction and to reunite the UK IMS entity with the US IMS entity,” said Jack Zhang, chief executive officer, Amphastar.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics